UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 303,159 Shares of CG Oncology, Inc. $CGON

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its holdings in shares of CG Oncology, Inc. (NASDAQ:CGON) by 28.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 761,807 shares of the company’s stock after selling 303,159 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in CG Oncology were worth $54,126,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Fiduciary Financial Advisors acquired a new position in shares of CG Oncology in the second quarter worth approximately $28,000. NFSG Corp acquired a new position in shares of CG Oncology during the 1st quarter valued at $34,000. Comerica Bank boosted its position in shares of CG Oncology by 100.4% during the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after purchasing an additional 515 shares in the last quarter. Fifth Third Bancorp bought a new position in CG Oncology in the first quarter worth approximately $74,000. Finally, KBC Group NV bought a new position in shares of CG Oncology in the 1st quarter worth $78,000. 26.56% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of CG Oncology in a research note on Friday, July 17th. JPMorgan Chase & Co. increased their price target on shares of CG Oncology from $91.00 to $96.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Truist Financial increased their price objective on CG Oncology from $82.00 to $85.00 and gave the company a “buy” rating in a report on Friday, August 7th. Wedbush increased their target price on shares of CG Oncology from $77.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price target on shares of CG Oncology in a report on Wednesday, July 29th. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $83.18.

Insider Activity

In related news, Director Brian Guan-Chyun Liu purchased 371,085 shares of CG Oncology stock in a transaction that occurred on Thursday, June 25th. The shares were acquired at an average cost of $66.87 per share, for a total transaction of $24,814,453.95. Following the transaction, the director directly owned 1,886,236 shares in the company, valued at $126,132,601.32. The trade was a 24.49% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Leonard E. Post sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $74.54, for a total transaction of $74,540.00. Following the completion of the transaction, the director owned 1,000 shares in the company, valued at $74,540. This represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 37,129 shares of company stock valued at $2,683,857. Corporate insiders own 4.80% of the company’s stock.

CG Oncology Price Performance

CGON stock opened at $74.59 on Thursday. CG Oncology, Inc. has a one year low of $26.92 and a one year high of $80.97. The firm has a 50 day simple moving average of $73.54 and a two-hundred day simple moving average of $67.04. The stock has a market cap of $6.61 billion, a PE ratio of -27.73 and a beta of 0.24.

CG Oncology (NASDAQ:CGON) last released its earnings results on Thursday, August 6th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.24). The firm had revenue of $1.16 million during the quarter, compared to the consensus estimate of $0.36 million. CG Oncology had a negative net margin of 3,602.68% and a negative return on equity of 25.20%. On average, research analysts expect that CG Oncology, Inc. will post -3.27 EPS for the current fiscal year.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.